Can We REVERSE Cancer Drug Resistance? The New Science of Fighting Cancer | Dr. John Yu, MD - Founder and CEO, Kairos Pharma - Professor and Clinical Chief of Neurosurgery, Cedars-Sinai

Send us Fan MailCancer doesn't just sit there while we attack it. It evolves.We give a patient a powerful drug. The tumor shrinks. It looks like we've won.But somewhere inside that tumor may be a small population of cells that figured out how to survive. Those cells can eventually multiply, the cancer returns, and the drug that once worked no longer works.So what if, instead of continually chasing cancer with newer and newer drugs, we could turn off the biological escape routes that allow cancer to become resistant in the first place?Dr. John Yu, MD is the Founder and CEO of Kairos Pharma ( https://kairospharma.com/ ), a clinical-stage oncology company spun out of Cedars-Sinai Medical Center that is developing therapies designed to overcome cancer drug resistance and immune suppression.Dr. Yu is also Professor and Clinical Chief of Neurosurgery at Cedars-Sinai and Director of Surgical Neuro-Oncology ( https://www.cedars-sinai.org/provider/john-yu-2181236.html ). His career sits at a fascinating intersection of neurosurgery, immunology and cancer biology.Dr. Yu earned undergraduate degrees in biology and French from Stanford University, his MD from Harvard Medical School through the Harvard-MIT program, completed his neurosurgery residency at Massachusetts General Hospital, and pursued immunology research at the Institut Pasteur in Paris.Over the course of his career, Dr. Yu has developed eight FDA investigational drugs and holds multiple patents spanning immunotherapy and nanotechnology.At Kairos, that scientific journey has led to a particularly interesting strategy: targeting CD105, also known as endoglin, a protein that appears to become elevated as tumors develop resistance to certain cancer therapies.The company's lead candidate, ENV105, is an antibody designed to inhibit CD105 and potentially re-sensitize resistant tumors to therapies that had stopped working. Kairos is currently evaluating ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer studies.On this episode we talk about one of the great challenges in modern oncology - why cancer becomes resistant, whether that resistance can actually be reversed, and whether we can turn some of our existing cancer drugs back into powerful weapons against the disease.#Cancer #CancerResearch #CancerTreatment #CancerDrugResistance #Oncology #Immunotherapy #PrecisionMedicine #Biotechnology #Biotech #DrugDevelopment #CancerTherapy #ProstateCancer #LungCancer #LungCancerResearch #ProstateCancerResearch #ImmunoOncology #TargetedTherapy #DrugResistance #CancerBiology #CD105 #Endoglin #ENV105 #KairosPharma #JohnYu #MedicalResearch #Pharma #HealthcareInnovation #CancerScience #ClinicalTrials #ProgressPotentialAndPossibilitiesSupport the show